IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sells $108,160.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Bruce L. Claflin sold 200 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which is available through this link.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $517.94 on Thursday. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The stock has a market capitalization of $42.78 billion, a price-to-earnings ratio of 50.14, a PEG ratio of 4.23 and a beta of 1.27. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The stock’s fifty day simple moving average is $510.61 and its 200 day simple moving average is $522.08.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Atria Investments Inc lifted its holdings in shares of IDEXX Laboratories by 11.5% in the first quarter. Atria Investments Inc now owns 4,549 shares of the company’s stock valued at $2,456,000 after purchasing an additional 470 shares in the last quarter. Swedbank AB acquired a new stake in IDEXX Laboratories during the 1st quarter worth about $21,013,000. LRI Investments LLC purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $57,000. Virtu Financial LLC increased its holdings in shares of IDEXX Laboratories by 264.4% in the 1st quarter. Virtu Financial LLC now owns 4,180 shares of the company’s stock valued at $2,256,000 after purchasing an additional 3,033 shares during the period. Finally, Wahed Invest LLC lifted its position in shares of IDEXX Laboratories by 17.1% in the first quarter. Wahed Invest LLC now owns 1,614 shares of the company’s stock worth $871,000 after purchasing an additional 236 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the subject of several recent analyst reports. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. raised their target price on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a research note on Tuesday, January 30th. Barclays decreased their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $580.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.